Breast cancer (Tokyo, Japan)最新文献

筛选
英文 中文
TBK1 as a key regulator in breast cancer: opportunities for targeted therapy. TBK1作为乳腺癌的关键调节因子:靶向治疗的机会
IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2026-11-13 DOI: 10.1007/s12282-026-01928-2
Helal F Hetta, Fawaz E Alanazi, Salwa Qasim Bukhari, Zinab Alatawi, Mashan L Abdullah, Ali S Alfardan, Mohammed A Al-Hamamah, Fahad Abdullah Alshahrani, Fahad O Alatawi, Tareq Nayef AlRamadneh, Noura H Abd Ellah, Yasmin N Ramadan, Ahmed A Kotb
{"title":"TBK1 as a key regulator in breast cancer: opportunities for targeted therapy.","authors":"Helal F Hetta, Fawaz E Alanazi, Salwa Qasim Bukhari, Zinab Alatawi, Mashan L Abdullah, Ali S Alfardan, Mohammed A Al-Hamamah, Fahad Abdullah Alshahrani, Fahad O Alatawi, Tareq Nayef AlRamadneh, Noura H Abd Ellah, Yasmin N Ramadan, Ahmed A Kotb","doi":"10.1007/s12282-026-01928-2","DOIUrl":"https://doi.org/10.1007/s12282-026-01928-2","url":null,"abstract":"<p><p>TANK-binding kinase 1 (TBK1) is a serine/threonine kinase that plays a critical role in innate immunity, inflammation, and cellular responses to stress. Recent studies have highlighted the pleiotropic roles of TBK1 in cancer. It has been shown to coordinate processes such as inflammation, autophagy, cell cycle progression, and cell death. TBK1 overexpression, aberrant kinase activation (pSer172), and cancer cell functional dependency have each been linked to tumorigenesis, metastasis, and therapeutic resistance. TBK1 is structurally organized into specific domains that are implicated in the mechanisms of its activation and the engagement of different adaptor proteins, dictating its subcellular location and function in different contexts. Phosphorylation, together with ubiquitination, are prominent post-translational modifications that govern TBK1 activity and contribute to several nodes of therapeutic intervention. Within breast cancer, TBK1 modulates both tumor-intrinsic pathways and tumor-extrinsic pathways, regulating not only cancer cell survival and proliferation but also the tumor microenvironment. Preclinical data indicate that inhibition of TBK1 could inhibit tumor growth and sensitize tumors to traditional and immune-based therapies. Nevertheless, the intricate regulation of TBK1 and context-dependent functions demonstrate the requirement for subtle therapeutic interventions, possibly involving combinatorial therapies. In this review, we summarize current literature about TBK1's structural features, regulation, and activities in breast cancer; review the rapidly growing evidence implicating TBK1 as a target for therapy; and consider ways of translating these insights into clinical practice in the future. Deciphering how TBK1 exerts distinct roles will open up new opportunities for targeted therapy for breast cancer and possibly other cancers.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149414742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Claims-defined adrenal insufficiency, hypothyroidism, and type 1 diabetes after immune checkpoint inhibitor initiation in patients with triple-negative breast cancer in Japan. 日本三阴性乳腺癌患者免疫检查点抑制剂启动后,声称定义肾上腺功能不全、甲状腺功能减退和1型糖尿病
IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2026-11-11 DOI: 10.1007/s12282-026-01940-6
Chitose Kawamura, Masao Iwagami, Hiroko Bando
{"title":"Claims-defined adrenal insufficiency, hypothyroidism, and type 1 diabetes after immune checkpoint inhibitor initiation in patients with triple-negative breast cancer in Japan.","authors":"Chitose Kawamura, Masao Iwagami, Hiroko Bando","doi":"10.1007/s12282-026-01940-6","DOIUrl":"https://doi.org/10.1007/s12282-026-01940-6","url":null,"abstract":"<p><strong>Background: </strong>The incidence of treated adrenal insufficiency, hypothyroidism, and type 1 diabetes after immune checkpoint inhibitor (ICI) treatment for triple-negative breast cancer (TNBC) has not been fully characterized in real-world clinical practice in Japan.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the JMDC claims database, which includes employees of Japanese companies and their dependents. Patients aged 18-74 years with TNBC who received atezolizumab or pembrolizumab between January 2005 and June 2025 were included. Early-stage and advanced TNBC were identified based on the treatment regimen at ICI initiation. We examined the incidence rates and time to onset of claims-defined adrenal insufficiency, hypothyroidism, and type 1 diabetes separately in the two cohorts.</p><p><strong>Results: </strong>The study included 569 patients with early-stage TNBC (median age, 50.8 years) and 254 with advanced TNBC (median age, 52.8 years). In early-stage TNBC, the incidence rates (95% CIs) of adrenal insufficiency and hypothyroidism were 5.6 (4.0-7.8) and 12.7 (10.0-16.0) cases/100 person-years (PY), respectively. The median times to onset (IQRs) were 124 (86-215) and 117 (89-196) days, respectively. In advanced TNBC, the incidence rates (95% CIs) of adrenal insufficiency and hypothyroidism were 1.4 (0.53-3.8) and 9.2 (6.1-13.8) cases/100 PY, respectively. The median time to onset of hypothyroidism was 84 (63-105) days. Type 1 diabetes was rare.</p><p><strong>Conclusions: </strong>This study provides real-world estimates of claims-defined endocrine outcomes after ICI initiation separately in patients with early-stage and advanced TNBC in Japan.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study. CDK4/6抑制剂治疗er阳性/ her2阴性转移性乳腺癌后依维莫司基治疗的实际结果:一项基于多中心登记的研究
IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2026-11-10 DOI: 10.1007/s12282-026-01931-7
Hikari Kiyohara, Toru Hanamura, Yasuaki Sagara, Minoru Miyashita, Shigehira Saji, Naoki Niikura
{"title":"Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study.","authors":"Hikari Kiyohara, Toru Hanamura, Yasuaki Sagara, Minoru Miyashita, Shigehira Saji, Naoki Niikura","doi":"10.1007/s12282-026-01931-7","DOIUrl":"https://doi.org/10.1007/s12282-026-01931-7","url":null,"abstract":"<p><strong>Background: </strong>Everolimus-based endocrine therapy is used for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER-positive/HER2-negative) metastatic breast cancer after cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment, but factors associated with treatment durability remain unclear. We evaluated real-world outcomes and associated factors.</p><p><strong>Methods: </strong>This multicenter retrospective registry study included patients who received everolimus-based endocrine therapy after CDK4/6 inhibitor treatment. The primary endpoint was time to treatment failure (TTF). Overall survival (OS), treatment response, and exploratory post-TTF survival were also evaluated. Associations were analyzed using Firth-penalized Cox and logistic regression models.</p><p><strong>Results: </strong>Among 169 eligible patients, median TTF and OS were 4.1 months (95% confidence interval [CI], 3.2-4.8) and 28.7 months (95% CI, 24.9-39.0), respectively. Non-ductal histology, progesterone receptor (PgR) expression <10%, and prior chemotherapy were independently associated with shorter TTF. Prior chemotherapy and metastases involving four or more organs were independently associated with shorter OS. Low PgR expression was independently associated with failure to achieve disease control and was also associated with failure to achieve objective response in univariable analysis. Post-TTF survival did not differ significantly by histologic subtype or PgR expression but was shorter in patients with prior chemotherapy or metastases involving four or more organs. Increasing numbers of adverse clinical factors were associated with progressively shorter TTF and OS.</p><p><strong>Conclusions: </strong>Outcomes varied according to tumor characteristics, prior treatment, and metastatic burden. Histologic subtype and PgR expression were associated with treatment durability, whereas prior chemotherapy and extensive metastatic burden were associated with overall prognosis. The exploratory risk stratification based on these routinely available factors warrants external validation.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149389376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility and safety of intraoperative photodynamic diagnosis using 5-aminolevulinic acid in breast cancer surgery. 5-氨基乙酰丙酸在乳腺癌手术中术中光动力学诊断的可行性和安全性。
IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2026-11-06 DOI: 10.1007/s12282-026-01934-4
Haruru Kotani, Ayako Isogai, Akira Nakakami, Ayumi Kataoka, Akiyo Yoshimura, Masaya Hattori, Masataka Sawaki, Fumikata Hara, Waki Hosoda, Hiroji Iwata
{"title":"Feasibility and safety of intraoperative photodynamic diagnosis using 5-aminolevulinic acid in breast cancer surgery.","authors":"Haruru Kotani, Ayako Isogai, Akira Nakakami, Ayumi Kataoka, Akiyo Yoshimura, Masaya Hattori, Masataka Sawaki, Fumikata Hara, Waki Hosoda, Hiroji Iwata","doi":"10.1007/s12282-026-01934-4","DOIUrl":"https://doi.org/10.1007/s12282-026-01934-4","url":null,"abstract":"<p><strong>Purpose: </strong>Intraoperative margin assessment remains a clinical challenge in breast cancer surgery. We conducted a prospective pilot study to evaluate the feasibility, safety, and diagnostic performance of 5-aminolevulinic acid (5-ALA)-based photodynamic diagnosis (PDD) using a commercially available imaging system in Japan.</p><p><strong>Methods: </strong>Patients with primary breast cancer scheduled for mastectomy and tumor size > 2 cm received oral 5-ALA (20 mg/kg) 2-4 h before surgery. Excised specimens were incised immediately after resection and examined under white light and blue-light PDD. Punch biopsies were obtained from areas classified by gross inspection and PDD findings. Pathology served as the reference standard. Primary endpoints were diagnostic odds ratio (DOR) and safety; secondary endpoints included sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).</p><p><strong>Results: </strong>Ten patients received 5-ALA. PDD visualization was feasible in 6 cases when specimens were examined within 10 min after excision. A total of 33 punch biopsies were analyzed. Compared with gross inspection alone (sensitivity 84.6%, specificity 85.0%, DOR 31.2, 95% CI 4.5-217.6), the addition of PDD was associated with a sensitivity of 92.3%, specificity of 80.0%, and DOR of 48.0 (95% CI 4.7-486.3); the confidence intervals overlapped substantially. PDD identified a grossly occult tumor focus. No adverse events related to 5-ALA were observed.</p><p><strong>Conclusions: </strong>In this prospective pilot study, intraoperative 5-ALA-based PDD was feasible and safe in breast cancer specimens. The addition of fluorescence information may improve diagnostic performance compared with gross assessment alone, although the small number of evaluable cases means that these estimates are exploratory and hypothesis-generating rather than confirmatory. Further studies are warranted to determine its clinical utility in breast-conserving surgery.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149358576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal PRO-CTCAE assessment in patients with HR+/HER2 - metastatic breast cancer initiating palbociclib: feasibility and symptom trajectories in a multicenter prospective cohort study. HR+/HER2 -转移性乳腺癌患者开始帕博西尼的纵向PRO-CTCAE评估:多中心前瞻性队列研究的可行性和症状轨迹
IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2026-11-06 DOI: 10.1007/s12282-026-01936-2
Takayuki Iwamoto, Yukari Uemura, Takashi Ishikawa, Azusa Jo, Hirohito Seki, Masahiro Kitada, Tsuyoshi Saito, Kimito Yamada, Shintaro Takao, Daisuke Takabatake, Toru Yokota, Yasuo Hozumi, Yuichiro Kikawa, Akimitsu Yamada, Uhi Toh, Hideki Nishimura, Hiroshi Kaise, Kazuhiko Yamagami, Reiki Nishimura, Kazutaka Narui, Hirofumi Mukai, Naruto Taira
{"title":"Longitudinal PRO-CTCAE assessment in patients with HR+/HER2 - metastatic breast cancer initiating palbociclib: feasibility and symptom trajectories in a multicenter prospective cohort study.","authors":"Takayuki Iwamoto, Yukari Uemura, Takashi Ishikawa, Azusa Jo, Hirohito Seki, Masahiro Kitada, Tsuyoshi Saito, Kimito Yamada, Shintaro Takao, Daisuke Takabatake, Toru Yokota, Yasuo Hozumi, Yuichiro Kikawa, Akimitsu Yamada, Uhi Toh, Hideki Nishimura, Hiroshi Kaise, Kazuhiko Yamagami, Reiki Nishimura, Kazutaka Narui, Hirofumi Mukai, Naruto Taira","doi":"10.1007/s12282-026-01936-2","DOIUrl":"https://doi.org/10.1007/s12282-026-01936-2","url":null,"abstract":"<p><strong>Background: </strong>Real-world data on PRO-CTCAE-assessed symptomatic toxicities in patients receiving palbociclib (PAL) plus endocrine therapy (ET) remain limited. We evaluated the feasibility of longitudinal assessment and characterized symptom profiles in a multicenter prospective cohort study.</p><p><strong>Methods: </strong>Patients with HR+/HER2 - metastatic breast cancer receiving PAL plus ET completed paper-based PRO-CTCAE at nine scheduled time points over 6 months. PRO-CTCAE availability was evaluated using the entire analysis population as a fixed denominator. Within-patient changes in general pain, joint pain, and fatigue were assessed, and longitudinal changes in severity were evaluated using cumulative link mixed models (CLMMs). Additional CLMMs examined differences in symptom trajectories between aromatase inhibitor (AI) and fulvestrant (FUL) groups after adjustment for baseline symptom severity, treatment line, and age.</p><p><strong>Results: </strong>Among 593 patients in the original cohort, 414 with baseline paper-based PRO-CTCAE assessments were analyzed. PRO-CTCAE availability was 100% at baseline and 66.4% at 6 months and was comparable across age groups and treatment lines. Significant overall time effects were observed for general pain (P < 0.001), joint pain (P < 0.001), and fatigue (P = 0.007). At 6 months, compared with baseline, the odds of greater symptom severity were lower for general pain (OR 0.49, 95% CI 0.34-0.71) but higher for joint pain (OR 2.36, 95% CI 1.59-3.52) and fatigue (OR 1.82, 95% CI 1.27-2.60). No significant time-by-ET interactions were observed for these symptoms.</p><p><strong>Conclusions: </strong>Repeated paper-based PRO-CTCAE assessment was feasible and identified distinct longitudinal trajectories of general pain, joint pain, and fatigue during PAL plus ET.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149358577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonlinear association between age and volumetric breast density in Japanese women. 日本女性年龄与乳腺体积密度的非线性关系。
IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2026-11-05 DOI: 10.1007/s12282-026-01937-1
Mai Matsubara, Takayoshi Uematsu, Takahiro Ito, Kumiko Ogawa, Miki Miyauchi, Kensei Shirata, Kenta Murotani, Kazuaki Nakashima
{"title":"Nonlinear association between age and volumetric breast density in Japanese women.","authors":"Mai Matsubara, Takayoshi Uematsu, Takahiro Ito, Kumiko Ogawa, Miki Miyauchi, Kensei Shirata, Kenta Murotani, Kazuaki Nakashima","doi":"10.1007/s12282-026-01937-1","DOIUrl":"https://doi.org/10.1007/s12282-026-01937-1","url":null,"abstract":"<p><strong>Background: </strong>Volumetric breast density (VBD) is influenced by age, body mass index (BMI), and reproductive factors, yet the shape of the age-VBD association and age-specific VBD distributions in Japanese women remain incompletely characterized. We examined the associations of age, BMI, menopausal status, and parity with software-derived VBD and characterized age-specific VBD distributions, including the proportion of women with VBD ≥ 7.5%.</p><p><strong>Methods: </strong>This cross-sectional study included 719 asymptomatic Japanese women undergoing screening mammography (mean age, 58.7 ± 12.6 years; range, 20-87 years) in whom no breast lesion was identified. VBD was quantified using Volpara Density. Age was modeled using restricted cubic splines, adjusted for BMI, menopausal status, and parity. Regression analyses used 672 complete cases. Mean VBD ≥ 7.5% defined volumetrically dense breasts.</p><p><strong>Results: </strong>Overall, 72.7% (523/719) had VBD ≥ 7.5%. Mean VBD was 17.34%, 13.41%, 11.01%, and 11.72% at ages 40-49, 50-59, 60-69, and 70-79 years, respectively, and 16.81% versus 11.85% in pre- versus postmenopausal women. Age was associated with VBD (P < 0.001), with significant nonlinearity (P = 0.027); adjusted VBD was lower with increasing age until the mid-60s and then largely plateaued. Higher BMI (β = -1.08; 95% CI, - 1.20 to - 0.97; P < 0.001) and parity (β = -2.21; 95% CI, - 3.43 to - 0.98; P < 0.001) were independently associated with lower VBD, whereas menopausal status was not (β = -1.07; 95% CI, - 2.85 to 0.71; P = 0.239).</p><p><strong>Conclusions: </strong>Age was nonlinearly associated with VBD in Japanese women, plateauing after the mid-60s. VBD ≥ 7.5% was common, while BMI and parity remained independently associated with lower VBD.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting neoadjuvant chemotherapy efficacy in triple-negative breast cancer using DCE-MRI and mammographic texture. 应用DCE-MRI和乳房x线影像结构预测三阴性乳腺癌新辅助化疗的疗效。
IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2026-11-04 DOI: 10.1007/s12282-026-01932-6
Shubo Gao, Jing Luo, Jing Zhang, Guijuan Cao, Yang Yang, Xiang Wang, Youjuan Dong
{"title":"Predicting neoadjuvant chemotherapy efficacy in triple-negative breast cancer using DCE-MRI and mammographic texture.","authors":"Shubo Gao, Jing Luo, Jing Zhang, Guijuan Cao, Yang Yang, Xiang Wang, Youjuan Dong","doi":"10.1007/s12282-026-01932-6","DOIUrl":"https://doi.org/10.1007/s12282-026-01932-6","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This study aimed to develop and validate a predictive model integrating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) kinetic features and digital breast tomosynthesis (DBT) texture features for predicting pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC). Additionally, its predictive performance was compared with that of single-modality models.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;A total of 360 patients with pathologically confirmed TNBC who received NAC between January 2022 and December 2025 were retrospectively and consecutively collected. Patients were randomly allocated to a training set (n = 252) and a validation set (n = 108) at a 7:3 ratio. Pre-NAC DCE-MRI kinetic and DBT texture features were extracted. After feature selection using least absolute shrinkage and selection operator (LASSO) regression, DCE-MRI and DBT radiomics scores (Rad-scores) were constructed. A nomogram prediction model was then developed using multivariable logistic regression incorporating clinicopathological and laboratory indicators. Model discrimination, calibration, and clinical net benefit were evaluated using the receiver operating characteristic curves, calibration curves, and decision curve analysis, respectively. These results were subsequently compared with those of a clinical-only model and single-modality combined models.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The pCR rates in the training and validation sets were 41.67% and 40.74%, respectively. Multivariable logistic regression identified Ki-67 proliferation index, maximum tumor diameter, background parenchymal enhancement score, neutrophil-to-lymphocyte ratio, lactate dehydrogenase level, DCE-Rad score, and DBT-Rad score as independent predictors of pCR (P &lt; 0.05). The dual-modality nomogram achieved area under the curve (AUC) values of 0.784 (95% CI: 0.718-0.851) in the training set and 0.759 (95% CI: 0.644-0.873) in the validation set, outperforming the clinical-only model (0.727), the clinical plus DCE-Rad score model (0.761), and the clinical plus DBT-Rad score model (0.766). Calibration curves showed good agreement between predicted probabilities and actual outcomes. Furthermore, decision curve analysis confirmed the clinical net benefit of the proposed model.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The multimodal radiomics fusion model based on DCE-MRI kinetic and DBT texture features effectively predicts pCR following NAC in TNBC patients. Its predictive performance is superior to that of single-modality models. Consequently, this model offers a non-invasive imaging tool for individualized pretreatment efficacy assessment. Nevertheless, further multicenter external validation is required to confirm its generalizability. For now, it should be viewed as a decision‑support aid that informs rather than dictates treatment choices, with specific actionable thresholds to be ","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methodological considerations in evaluating bioelectrical impedance and quality of life in breast cancer: NACT confounding, generalizability of standing devices, and fluid asymmetries. 评价乳腺癌中生物电阻抗和生活质量的方法学考虑:NACT混杂、站立装置的普遍性和流体不对称。
IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2026-11-03 DOI: 10.1007/s12282-026-01938-0
Surhan Indra
{"title":"Methodological considerations in evaluating bioelectrical impedance and quality of life in breast cancer: NACT confounding, generalizability of standing devices, and fluid asymmetries.","authors":"Surhan Indra","doi":"10.1007/s12282-026-01938-0","DOIUrl":"https://doi.org/10.1007/s12282-026-01938-0","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149329741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of febrile neutropenia in breast cancer chemotherapy despite the prophylactic use of pegfilgrastim: a retrospective analysis. 尽管预防性使用pegfilgrastim,乳腺癌化疗中发热性中性粒细胞减少的风险:回顾性分析。
IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2026-11-01 Epub Date: 2026-08-14 DOI: 10.1007/s12282-026-01907-7
Hiroki Kusama, Yoshiya Horimoto, Kyoko Iwai, Yuki Kitaoku, Fujina Takeda, Ryo Hamaoka, Minami Iwai, Mizuki Mizuuchi, Tomoka Ushio, Kyoko Orimoto, Takashi Ishikawa
{"title":"Risk of febrile neutropenia in breast cancer chemotherapy despite the prophylactic use of pegfilgrastim: a retrospective analysis.","authors":"Hiroki Kusama, Yoshiya Horimoto, Kyoko Iwai, Yuki Kitaoku, Fujina Takeda, Ryo Hamaoka, Minami Iwai, Mizuki Mizuuchi, Tomoka Ushio, Kyoko Orimoto, Takashi Ishikawa","doi":"10.1007/s12282-026-01907-7","DOIUrl":"10.1007/s12282-026-01907-7","url":null,"abstract":"<p><strong>Background: </strong>Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is used to prevent febrile neutropenia (FN) in breast cancer patients undergoing chemotherapy. However, a small subset of patients still develops FN. This study aimed to assess the real-world incidence of FN and identify potential risk factors in this specific population.</p><p><strong>Methods: </strong>This retrospective study included breast cancer patients who received pegfilgrastim prophylaxis at Tokyo Medical University Hospital between February 2019 and December 2024. Inclusion required pegfilgrastim use at least once during chemotherapy. FN was defined as an absolute neutrophil count below 500/µL (or a predicted ANC below 1,000/µL) and an axillary temperature 37.5 °C or higher. Cases of FN and associated risk factors were analyzed using logistic regression models.</p><p><strong>Results: </strong>This study included 378 patients (median age 53). Tumor subtypes were luminal (50.0%), HER2-positive (20.9%), and triple-negative (29.1%), with dose-dense regimens being the most common (55.8%). Of 2,784 total chemotherapy administrations, pegfilgrastim was used in 2,125 cycles (76.3%). The incidence of FN despite pegfilgrastim was 2.1% (8/378), with the highest rate observed in immune checkpoint inhibitor-containing regimens (9.1%, 2/22). Multivariate analysis identified a low baseline platelet count as a significant independent risk factor for combined FN and grade 3-4 neutropenia (OR: 0.98; 95% CI: 0.96-0.99; P = 0.02).</p><p><strong>Conclusion: </strong>Although pegfilgrastim is effective, FN still occurs in a small percentage of patients. A low baseline platelet count was associated with an increased risk of FN or severe neutropenia despite pegfilgrastim prophylaxis, though this finding requires confirmation in larger studies given the limited number of events.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1305-1311"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148763419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term outcomes of invasive lobular carcinoma compared with invasive ductal carcinoma in HR-positive/HER2-negative breast cancer: a focus on luminal subtypes. hr阳性/ her2阴性乳腺癌浸润性小叶癌与浸润性导管癌的长期预后比较:聚焦于管腔亚型
IF 2.9
Breast cancer (Tokyo, Japan) Pub Date : 2026-11-01 Epub Date: 2026-10-03 DOI: 10.1007/s12282-026-01922-8
Sayoko Kakimoto, Hiroyuki Yamamoto, Junki Koike, Koichiro Tsugawa
{"title":"Long-term outcomes of invasive lobular carcinoma compared with invasive ductal carcinoma in HR-positive/HER2-negative breast cancer: a focus on luminal subtypes.","authors":"Sayoko Kakimoto, Hiroyuki Yamamoto, Junki Koike, Koichiro Tsugawa","doi":"10.1007/s12282-026-01922-8","DOIUrl":"10.1007/s12282-026-01922-8","url":null,"abstract":"<p><strong>Background: </strong>Invasive lobular carcinoma (ILC) differs from invasive ductal carcinoma (IDC) in clinicopathological characteristics, treatment responsiveness, and recurrence patterns. However, its long-term prognostic significance, particularly in hormone receptor (HR)-positive/HER2-negative disease, remains incompletely understood.</p><p><strong>Methods: </strong>We retrospectively analyzed 2,423 women with clinical stage I-III breast cancer who underwent partial mastectomy or total mastectomy between January 2013 and December 2017, including 2,262 patients with IDC and 161 with ILC. The primary endpoint was invasive breast cancer-free survival (iBCFS), and overall survival (OS) was evaluated as a secondary endpoint. Multivariable Cox proportional hazards models were used to compare outcomes between ILC and IDC. Subtype-specific analyses were restricted to HR-positive/HER2-negative luminal A-like and luminal B-like tumors defined according to the St. Gallen 2013 criteria. Exploratory analyses assessed the associations of neoadjuvant and adjuvant chemotherapy with outcomes.</p><p><strong>Results: </strong>Compared with IDC, ILC was more frequently ER-positive/HER2-negative, had lower Ki-67, and presented with more advanced pathological tumor burden. Five-year iBCFS was 84.9% in ILC and 91.5% in IDC (log-rank p = 0.053). In the adjusted overall model, ILC tended to be associated with poorer iBCFS (hazard ratio [HR] 1.43, 95% confidence interval [CI] 0.94-2.19; p = 0.096). In subtype-specific analyses, ILC was not significantly associated with iBCFS in luminal A-like disease (HR 1.15, 95% CI 0.67-1.98; p = 0.619), whereas the adverse prognostic association of ILC was more apparent in luminal B-like disease (HR 1.47, 95% CI 1.03-2.09; p = 0.033). The histology-by-subtype interaction was not statistically significant. In luminal disease, neoadjuvant chemotherapy was not independently associated with improved outcomes after adjustment for pretreatment clinical stage, whereas adjuvant chemotherapy was associated with better iBCFS in the combined luminal ILC group.</p><p><strong>Conclusions: </strong>ILC tended to be associated with poorer long-term invasive outcomes than IDC, particularly in HR-positive/HER2-negative disease. The adverse prognostic association of ILC was more apparent in luminal B-like tumors than in luminal A-like tumors. These findings support a risk-adapted approach to ILC that integrates histology, tumor burden, and proliferative activity. Further validation in larger prospective studies is warranted.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1433-1442"},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149122676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书